ArticleClinical and molecular hepatology2026
Extending MET-TRIB3 axis research in hepatocellular carcinoma: Immune contexture and patient subgroups: Letter to the editor on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".
Article in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correspondence to letter to the editor on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".Clinical and molecular hepatology · 2026Article
- Reply to correspondence on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".Clinical and molecular hepatology · 2026Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.